MDM2 and small cell lung carcinoma: Alternatively, the direct targeting of the proto-oncogenic E3 ligase Mdm2 is the basis of the anti-infective drug nitroxoline (NXQ), which is potentially useful for therapy of small cell lung cancer [59].